IRVINE, Calif., April 9, 2007 (PRIME NEWSWIRE) -- "As most small cap investors are neither medical doctors or biotechnology scientists, a critical element in the evaluation of a company is the progress made toward Food and Drug Administration approvals," stated SmallCap Sentinel analyst D.R. Clark. "And sometimes companies give investors a glimpse of their potential FDA future."
"For example, MIV Therapeutics Inc. (OTCBB:MIVT), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, just announced that a recent company-sponsored bench test confirmed that merging Biosync Scientific's certified bare metal stent platform, which MIVT recently acquired, with the company's polymer-free drug delivery system met critical 'FDA Draft Guidance for the Submission of Research and Marketing Applications for Interventional Cardiology Devices' requirements for in vitro mechanical fatigue testing," Clark noted. "Clearly, this is a strong indicator."
MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies.
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available at www.SmallCapSentinel.com and will address stents and stent related companies including MIV Therapeutics, Inc. (OTCBB:MIVT), Angiotech Pharmaceuticals Inc. (Nasdaq:ANPI), Johnson & Johnson Inc. (NYSE:JNJ), and Boston Scientific CP (NYSE:BSX). The report will place specific emphasis on drug eluting stents, their design, application, and imperative need.
Interested parties may view additional information about MIVT via this direct link: http://www.trilogy-capital.com/autoir/mivt_autoir.html
Individuals may also register to receive free future reports at: http://stockupticks.com/register.html
Companies interested in being featured in SmallCap Sentinel can use the contact info below.
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and shouldn't be used as basis for any investment decision. MP isn't an investment advisor and this report isn't investment advice. MP has been paid $1500 by MIV Therapeutics Inc. for preparation and distribution of this report and other advertising services over a 45 day period. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding subject companies.